PALANDRI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 388
EU - Europa 228
AS - Asia 105
AF - Africa 1
Totale 722
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 387
IE - Irlanda 58
SE - Svezia 55
HK - Hong Kong 51
IT - Italia 46
RU - Federazione Russa 34
CN - Cina 29
SG - Singapore 13
DE - Germania 10
CH - Svizzera 9
JO - Giordania 8
GB - Regno Unito 7
UA - Ucraina 5
FI - Finlandia 4
TR - Turchia 4
CA - Canada 1
SC - Seychelles 1
Totale 722
Salva come PNG Salva come JPEG
Città #
Chandler 78
Dublin 58
Ashburn 50
Hong Kong 34
Altamura 24
Lawrence 24
Fairfield 18
Moscow 15
Princeton 14
Shanghai 13
Beijing 12
Cambridge 12
Seattle 12
Boston 11
Wilmington 10
Bern 9
Jacksonville 9
San Diego 9
Woodbridge 9
Boardman 8
Medford 8
Washington 8
Buffalo 7
Houston 6
Singapore 6
Andover 4
Izmir 4
Ann Arbor 3
Bremen 3
Brugherio 3
London 3
Hangzhou 2
Kent 2
Norwalk 2
Pistoia 2
Rome 2
San Mateo 2
Arnsberg 1
Chicago 1
Falls Church 1
Florence 1
Fontevivo 1
Genoa 1
Hillsboro 1
Lappeenranta 1
New Bedfont 1
Redmond 1
Reston 1
Shenzhen 1
Toronto 1
Treviso 1
Trumbull 1
West Jordan 1
Totale 512
Salva come PNG Salva come JPEG
Nome #
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B 2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 75
A modified adenine chemically coupled to the allergen molecule of Dermatophagoides pteronyssinus redirects allergen-specific Th2 cells 62
Total serum IgE levels influence the in vitro detection of ss-lactams-specific IgE antibodies 59
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 59
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 44
A modified adenine chemically coupled to allergen molecule(s) induce Interferon-gamma production and down regulate IL-4 and IL-5 in Th2 specific T cells 42
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 41
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 41
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey 41
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study 39
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis 38
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 34
Long-term follow-up of recovered MPN patients with COVID-19 32
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 29
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study 21
Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis 18
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis 15
null 15
Breakthrough infections in MPN-COVID vaccinated patients 14
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT 12
Incidence of blast phase in myelofibrosis according to anemia severity 9
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 2
Totale 742
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.170
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.170
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202048 0 1 0 1 5 5 4 8 5 7 7 5
2020/202147 3 2 4 3 3 5 0 10 4 6 4 3
2021/202278 3 1 3 1 0 3 0 23 3 1 10 30
2022/2023319 24 73 20 17 23 45 32 21 38 6 8 12
2023/2024201 5 14 25 18 21 32 7 44 3 14 3 15
2024/202533 19 14 0 0 0 0 0 0 0 0 0 0
Totale 742